Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells.

International journal of oncology

Volumn 25, Issue 3, 2004, Pages 677-684

  Komdeur, R ^a   Meijer, C ^a   Van Zweeden, M ^a   De Jong, S ^a   Wesseling, J ^a   Hoekstra, H J ^a   van der Graaf, W T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; DOXORUBICIN; IFOSFAMIDE; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; RHABDOMYOSARCOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IFOSFAMIDE; MEMBRANE GLYCOPROTEINS; RHABDOMYOSARCOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 16644378847     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.25.3.677     Document Type: Article

References (0)